Cat. No. 3836
Chemical Name: 4-[Bis(1,3-benzodioxol-5-yl)hydroxy
Biological ActivityPotent and selective MAGL inhibitor. Blocks hydrolysis of the endocannabinoid 2-arachidonyl glycerol (2-AG) in vivo in the mouse brain (IC50 = 8 nM). Potentiates depolarization-induced suppression of excitability in cerebellar Purkinje neurons. Exhibits >300-fold selectivity for MAGL over FAAH in vitro. Attenuates nociception in neuropathic and inflammatory pain models. Also reduces free fatty acid levels in primary tumors.
Licensing InformationSold under license from The Scripps Research Institute.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Long et al (2009) Selective blockade of 2-arachidonylglycerol hydrolysis produces cannabinoid behavioral effects. Nat.Chem.Biol. 5 37. PMID: 19029917.
Pan et al (2009) Blockade of 2-arachidonylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling. J.Pharm.Exp.Ther. 331 591. PMID: 19666749.
Zhang et al (2012) Dysregulated lipid metabolism in cancer. World J.Biol.Chem. 3 167. PMID: 22937213.
Kinsey et al (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J.Pharmacol.Exp.Ther. 345 492. PMID: 23412396.
If you know of a relevant citation for this product please let us know.
Keywords: JZL 184, supplier, JZL184, MAGL, inhibitor, MAG, lipase, monoacylglycerol, lipase, inhibitors, MGL
Find multiple products by catalog number
New Products in this Area
Ces3 and Ces1f inhibitor968
Allosteric inhibitor of glutaminaseARN 272
FAAH-like anandamide transporter (FLAT) inhibitorML 349
Selective and reversible lysophospholipase 2 (LYPLA2) inhibitorJJKK 048
Potent and selective MAGL inhibitorML 348
Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor
July 7 - 11, 2015
Rio de Janeiro, Brazil